Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

BACKGROUND: Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because they release large amounts of various mediators that sustain the inflammatory network. Masitinib, a sel...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Vermersch, Patrick, Benrabah, Rabah, Schmidt, Nicolas, Zéphir, Hélène, Clavelou, Pierre, Vongsouthi, Cyrille, Dubreuil, Patrice, Moussy, Alain, Hermine, Olivier
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2012
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3467179/
https://ncbi.nlm.nih.gov/pubmed/22691628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-12-36
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky